AXT, Inc. (Nasdaq: AXTI) has postponed its 2026 annual meeting to June 4 after failing to achieve the required quorum, marking a governance setback as the semiconductor materials company pushes for shareholder approval on a key capital increase. The meeting, originally scheduled for May 15 at the company's Fremont, California headquarters, was adjourned with only about 48% of eligible shares represented by proxy, falling short of the majority needed under the company's bylaws.
Shareholder Vote on Share Increase
At the rescheduled meeting, AXT will seek shareholder approval to increase its authorized common shares from 70 million to 120 million. This move, if approved, would provide the company with greater flexibility to issue additional stock, particularly relevant after a significant equity raise and a sharp run-up in the stock price. The company has engaged Alliance Advisors, a proxy solicitation firm, to help secure more votes ahead of the June 4 reconvening.
Stock Performance and Market Context
AXT shares closed at $123.78 on Friday, gaining 7.65% in a volatile session that saw the stock hit an intraday high of $128.50 before pulling back. The rally reflects growing investor interest in indium phosphide (InP), a key material used in high-speed optical links for data centers and telecommunications, driven by the AI boom. For the first quarter, AXT reported revenue of $26.9 million, up from $19.4 million a year earlier, while its net loss narrowed to $1.6 million from $8.8 million in the prior-year period.
Capital Raise and Expansion Plans
CEO Morris Young described the current period as an incredibly exciting time for the company, citing a $632.5 million capital raise aimed at expanding InP capacity at Tongmei and advancing research, including development of 6-inch InP wafers. The offering, detailed in AXT's 10-Q filing, involved 8.56 million shares at $64.25 per share, plus an underwriter option for an additional 1.28 million shares, generating gross proceeds of approximately $632.5 million before expenses.
Regulatory and Competitive Risks
China's export controls on indium phosphide substrates, implemented in 2025, remain a significant headwind. AXT described obtaining export permits as its most significant challenge, warning that delays in permit approvals could disrupt revenue recognition and materially harm its business, financial condition, and results. The company also faces competition from larger players like Sumitomo and JX, which could pressure pricing and margins.
Analyst Sentiment
Wall Street remains cautious following the stock's sharp ascent. According to StockAnalysis data, the consensus rating on AXT is Hold, with an average price target of $57. Wedbush analyst Matt Bryson maintained a Buy rating and raised his target to $93, while B. Riley's Dave Kang kept a Hold rating with a $21 target, reflecting the wide divergence in views on the company's valuation and risk profile.
Outlook
The June 4 meeting represents a critical governance checkpoint for AXT. If the company again fails to achieve a quorum, it could face additional uncertainty just as investors weigh the pace of its expansion, export risks, and a stock price that has already surpassed many analyst targets. All proposals remain unchanged for the rescheduled meeting.
